Statements (28)
| Predicate | Object |
|---|---|
| gptkbp:instanceOf |
gptkb:monoclonal_antibody
immunotherapy |
| gptkbp:administeredBy |
intravenous infusion
|
| gptkbp:approvedBy |
gptkb:China
2019 |
| gptkbp:ATCCode |
L01FF10
|
| gptkbp:CASNumber |
1798286-23-4
|
| gptkbp:developedBy |
gptkb:Jiangsu_Hengrui_Medicine
|
| https://www.w3.org/2000/01/rdf-schema#label |
Camrelizumab
|
| gptkbp:legalStatus |
prescription only
|
| gptkbp:marketedAs |
gptkb:AiRuiKa
|
| gptkbp:mechanismOfAction |
immunotherapy
|
| gptkbp:routeOfAdministration |
intravenous
|
| gptkbp:sideEffect |
fatigue
pruritus hypothyroidism rash elevated liver enzymes reactive cutaneous capillary endothelial proliferation |
| gptkbp:target |
gptkb:PD-1
|
| gptkbp:UNII |
6Q1K1Y1A2E
|
| gptkbp:usedFor |
gptkb:non-small_cell_lung_cancer
gptkb:cancer gptkb:classical_Hodgkin_lymphoma hepatocellular carcinoma esophageal squamous cell carcinoma |
| gptkbp:bfsParent |
gptkb:Non-Small_Cell_Lung_Cancer
|
| gptkbp:bfsLayer |
6
|